Natera Q3 Earnings: Revenue Jumps 34% to $794 Million as Guidance Rises and a New CEO Takes Over
Natera Q3 Earnings: Revenue Jumps 34% to $794 Million as Guidance Rises and a New CEO Takes Over
Natera reported third-quarter revenue of $794.0 million, up 34.1% year over year, comfortably beating expectations as record test volumes powered the diagnostics company to another strong quarter. The company also raised its full-year guidance and announced a change at the top, with a new chief executive taking over on the same day the results landed.
Natera, which makes blood-based genetic tests for oncology, women's and reproductive health, and organ health, reported its third-quarter 2026 results on Thursday, November 5, 2026, after the market close. For investors who follow earnings season through the Zimbuck News page, this was a report with two stories running in opposite directions: a clear revenue beat and raised outlook on one side, and a wider-than-expected earnings-per-share loss on the other.
The Quarter in Numbers
The headline figures show a company growing quickly while still working toward consistent profitability on a reported basis. Revenue growth was the standout, and the loss narrowed sharply compared with a year earlier even though it missed analyst expectations.
- Revenue: $794.0 million — exactly $793.98 million — up 34.1% from $592.2 million a year earlier, and well ahead of the roughly $707.5 million consensus estimate
- GAAP EPS: a loss of -$0.42, missing the -$0.28 consensus, but narrower than the -$0.64 loss a year earlier
- Net loss: narrowed to $59.9 million from $87.5 million a year earlier
- Tests processed: a record of about 1.09 million tests, roughly 1.1 million, up about 22% from about 894,000 a year earlier
- Revenue true-ups: $32.3 million in the quarter, down from $55.1 million a year earlier
- Cash position: cash, cash equivalents and restricted cash of $1.097 billion at September 30, 2026
That combination matters. A revenue beat of this size, paired with a narrower net loss, points to operating leverage: more tests flowing through the same laboratory and commercial infrastructure. The EPS miss, meanwhile, is a reminder that reported profitability has not yet caught up with the top-line story, and it is why the EPS miss and the revenue beat pulled in opposite directions for anyone reading the report.

Why Revenue Grew So Fast
Management pointed to two main drivers behind the growth: higher test volumes and higher average selling prices. Processing about 1.09 million tests in a single quarter is a record for the company, and volume growth of roughly 22% shows demand is not relying on price alone.
The quality of the growth also improved. Revenue true-ups — adjustments linked to earlier testing periods — contributed $32.3 million in the quarter, down from $55.1 million a year earlier. In other words, a smaller share of this quarter's revenue came from true-ups than a year ago. Excluding revenue true-ups, growth was above 40%, which suggests the underlying business expanded even faster than the reported 34.1% headline.
Natera's best-known oncology test, Signatera, sits at the centre of that story. The company sells blood-based genetic tests across oncology, women's and reproductive health, and organ health, and oncology testing is where management sees the largest long-term opportunity. Readers who want a refresher on how to read company earnings results like this one, from revenue beats to EPS misses, will find it useful to compare the revenue, margin and guidance lines together rather than judging a report on a single number.
Guidance Raised for the Full Year
The clearest sign of management confidence came in the outlook. Natera raised its full-year 2026 revenue guidance to $3.005 billion to $3.035 billion, up from the previous range of $2.850 billion to $2.910 billion. That is a lift of about $140 million at the midpoint — a meaningful raise this late in the year, with only one quarter left to report.
The rest of the outlook was held steady. The gross-margin outlook was kept at 64% to 66%, and the company said it still expects positive cash flow. Selling, general and administrative spending was guided at $1.225 billion to $1.300 billion, with research and development guided at $825 million to $925 million. Holding margin guidance while raising revenue guidance implies management expects the extra revenue to arrive without a proportional jump in costs — the same operating-leverage pattern visible in the third-quarter numbers.
Investors discussing what a guidance raise of this size usually signals are comparing notes in the Zimbuck Market News group, where earnings reports from growth companies are a regular topic through the season.

A New CEO Takes Over
The results arrived alongside a leadership change. Chief executive Steve Chapman stepped down — he resigned on November 4, effective November 5 — and Solomon Moshkevich was appointed chief executive, effective immediately. Chapman is staying on as a consultant and adviser to the board, so the transition is structured as a handover rather than a clean break.
Leadership changes announced with earnings always deserve a careful read. On one hand, a new chief executive inherits a business that has just raised guidance and set an ambitious long-term target. On the other hand, a change at the top can also mean a shift in priorities, spending or timelines. The detail that the outgoing chief executive remains available to the board as a consultant and adviser is intended to preserve continuity while the new chief executive settles in. The full discussion of the quarter and the transition can be heard in the Motley Fool transcript of Natera's Q3 2026 earnings call.
The Goal: Double Revenue to $6 Billion by 2029
Management also set a long-term goal: double revenue to $6 billion by 2029. Against the new full-year 2026 guidance of just over $3 billion, that target implies roughly three more years of strong growth.
The company said the path to $6 billion rests mainly on growth in oncology testing, led by Signatera, along with average selling prices, international expansion, and pharma and data services. Importantly, the target assumes only a limited contribution from early cancer screening, which means management is presenting the goal as achievable from its existing and nearer-term businesses rather than depending on an unproven screening market.
That framing matters for how realistic the target looks. A doubling built on volume growth, pricing, international expansion and services is still ambitious — it requires execution across several fronts at once — but it is a different kind of ambition from one that depends on a single new product category succeeding. The third quarter, with record volumes and growth above 40% excluding true-ups, is the kind of evidence management will need to keep producing.
What to Watch Next
Three questions now frame the Natera story. First, can test volumes keep growing at a pace that supports the raised full-year guidance and the early steps toward $6 billion? Second, will reported profitability continue to narrow the gap with revenue growth, after a quarter in which the net loss improved to $59.9 million but EPS still missed consensus? Third, how will the new chief executive's priorities differ, if at all, from the plan laid out alongside his appointment?
The balance sheet gives the company room to execute. With $1.097 billion in cash, cash equivalents and restricted cash at September 30, 2026, and positive cash flow still expected for the year, Natera is not under immediate financial pressure while it invests in growth. The next quarterly report will be the first full test of the new leadership and of whether the momentum behind the guidance raise has carried into the final quarter of 2026.
Frequently Asked Questions
How much revenue did Natera report in Q3 2026?
Natera reported revenue of $794.0 million — exactly $793.98 million — up 34.1% from $592.2 million a year earlier. That beat the roughly $707.5 million consensus estimate.
Did Natera beat or miss earnings expectations?
Both, in different places. Revenue beat expectations clearly, but GAAP earnings per share came in at a loss of -$0.42, missing the -$0.28 consensus. The loss was still narrower than the -$0.64 recorded a year earlier, and the net loss narrowed to $59.9 million from $87.5 million.
What is Natera's new full-year 2026 guidance?
The company raised full-year 2026 revenue guidance to $3.005 billion to $3.035 billion, up from $2.850 billion to $2.910 billion — about a $140 million lift at the midpoint. Gross-margin guidance was kept at 64% to 66%, and positive cash flow is still expected.
Who is Natera's new CEO?
Solomon Moshkevich was appointed chief executive, effective immediately, after Steve Chapman resigned on November 4, effective November 5. Chapman stays on as a consultant and adviser to the board.
What drove Natera's revenue growth in the quarter?
Growth was driven by record test volumes — about 1.09 million tests processed, up about 22% — and by average selling prices. Excluding revenue true-ups of $32.3 million, growth was above 40%.
What is Natera's $6 billion revenue goal?
Management set a goal to double revenue to $6 billion by 2029, mainly through oncology testing growth led by Signatera, average selling prices, international expansion, and pharma and data services, assuming only a limited contribution from early cancer screening.
Natera's quarter combined a strong revenue beat, a raised outlook and a leadership handover — a lot for investors to weigh at once, and a good reminder to read the whole report rather than a single headline number. Join the conversation at zimbuck.com, where the community follows company earnings, market news and analyst debate as each report lands. This article is market news and general information only, not financial advice.